C-EV9IRejuvenate BioMed
AI drug discovery, combination therapeutics, healthspan platforms
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EV9I
C-EV9IC-EV9IAI drug discovery, combination therapeutics, healthspan platforms
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rejuvenate BioMed AI drug discovery, combination therapeutics, healthspan platforms
Rejuvenate Biomed is a Belgian clinical-stage biomedical company founded in 2017 by Ann Belien, PhD. The company develops proprietary combination drugs for age-related diseases using CombinAge, an AI-enabled in silico platform, and CelegAge, an in vitro and in vivo C. elegans and cell-culture platform. Its lead candidate RJx-01 is a proprietary oral combination drug for sarcopenia and is under evaluation in a fully enrolled Phase 2 trial in COPD-induced sarcopenia.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rejuvenate BioMed — Translational · Lower middle. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic